Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Busy address KBO
12 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Inhatarget Therapeutics from Charleroi, company number BE0732994752, closed financial year 2025 with a result of € -921,288 after tax. For that financial year Inhatarget Therapeutics recorded a gross margin of € 231,962 and equity of € 1.6 million. Compared with financial year 2024, the result moved from € -832,636 to € -921,288. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 24, 2026.
€ 1.6 million
▼ 28% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -921,288
▼ 11 % more loss than in 2024
Profit after tax over the fiscal year.
€ 669,909
▼ 1% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -921,288.
People and assets in 2025
5.2
▼ 0.6 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 376,442
▼ 5% vs 2024
€ 72,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 986
▼ 20% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 149,822
▼ 33% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 53,833
▼ 1% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 186,626 | € 74,708 | € 66,753 | € 231,962 | ▲ 247% |
| Profit after taxes | € -1,548,731 | € -922,680 | € -832,636 | € -921,288 | ▼ € 88,652 |
| Equity | € 3,841,043 | € 2,975,679 | € 2,164,146 | € 1,568,763 | ▼ 28% |
| Total debts | € 660,468 | € 578,677 | € 793,147 | € 587,779 | ▼ 26% |
| Cash | € 4,290,450 | € 214,320 | € 675,737 | € 669,909 | ▼ 1% |
| Retained profit | € -3,151,684 | € -922,680 | € -1,755,317 | € -921,288 | ▲ € 834,028 |
| Balance sheet total | € 4,501,511 | € 3,554,356 | € 2,957,294 | € 2,156,542 | ▼ 27% |
| Employees (FTE) | 6 | 5.5 | 5.8 | 5.2 | ▼ 0.6 |
Key figures of Inhatarget Therapeutics, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Inhatarget Therapeutics?
What happened at Inhatarget Therapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 921,288. Source: NBB ↗
- GENFLOW BIOSCIENCES became a director. NBB
- Mohamed Sebti became a director. NBB
- Karim Amighi became a director. NBB
- SAMBRINVEST & FREMOLUC HOLDING became a director. NBB
- S.M.B. TECHNOLOGY became a director. NBB
- New establishment in Charleroi. KBO
- Start of the company according to the CBE. KBO
In short
From € 1.5 million loss in 2022 to € 921,288 loss in 2025.
Paid € 349 in corporate taxes since 2022.
On average € 44,600 of value added per employee in 2025.
Management
The stake of THEODORUS IV, Sambrinvest & Fremoluc Holding comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
Inhatarget TherapeuticsBehind Inhatarget Therapeutics are FDC CONSULT, Mohamed Sebti, 50°North Ventures SRL, S.M.B. TECHNOLOGY, Karim Amighi and GENFLOW BIOSCIENCES. The shares are held by THEODORUS IV (34.3%) and Sambrinvest & Fremoluc Holding (15.2%).
Directors
According to the 2025 annual accounts
since 2019
Mohamed Sebti
Director
since 2020
Director · represented by Jean Van Nuwenborg
Also active at: EEBIC, BE ANGELS, Brussels South Charleroi BioPark Dev, THEODORUS III, THEODIRIS, ALLERINVEST, KABANDY, SEEDER FUND +13 more
since 2019
Director · represented by Arthur Deboek
since 2019
Karim Amighi
Director
since 2020
GENFLOW BIOSCIENCES
Director · represented by Eric Leire
since 2020
SAMBRINVEST & FREMOLUC HOLDING
Director · represented by Cédric Szpirer
since 2020
Shareholders
34.3%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rue Antoine de Saint-Exupéry 2
6041 Charleroi
Rue Auguste Piccard 48
6041 Charleroi
Active since 29 August 2019
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 12 companies are registered at this address.
All companies at this address →DIGICLOUD COMMUNICATION
€ 569,887 gross margin · 2025
MONKEY BRIDGE
€ 290,813 gross margin · 2025
eCADE
€ 0 revenue · 2025
MADEMOISELLE JO
€ 89,371 gross margin · 2025
BANANA NAVY
€ 82,010 gross margin · 2025
+7 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0732.994.752
- VAT number
- BE 0732.994.752
- Registered office
- Rue Antoine de Saint-Exupéry 2, 6041 Charleroi
- Names & denominations
- Inhatarget Therapeutics
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 29 August 2019
- Peppol
- Active · Active since 1 Jan 2001
- Contact
- [email protected]
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Overige gespecialiseerde wetenschappelijke en technische activiteiten